早期肝细胞癌根治性治疗前CT后行钆塞酸增强MRI的成本效益分析
本研究用决策分析模型比较两种初始检查策略:单纯动态多期CT与CT后追加钆塞酸增强MRI,用于指导55岁、Child-Pugh A级肝硬化、动态多期CT检出早期肝细胞癌患者的根治性治疗。钆塞酸增强MRI策略较常规CT策略获得更多生命年和质量调整生命年,增量成本效益比为11,957美元,低于50,000美元/质量调整生命年的成本效益阈值。
要点
- CT后追加钆塞酸增强MRI用于早期肝细胞癌分期,增量成本效益比为11,957美元。
- 该增量成本效益比低于50,000美元/质量调整生命年的成本效益阈值。
核心结论
- 在可接受根治性治疗(肝移植除外)的早期肝细胞癌患者中,CT后行钆塞酸增强MRI检出额外肝细胞癌具有成本效益。
- 作者认为,钆塞酸增强MRI的成本效益可在早期肝细胞癌分期管理中予以考虑。
研究设计与样本
- 决策分析模型,以55岁、动态多期CT检出早期肝细胞癌且Child-Pugh A级肝硬化的患者队列为起点。
- 比较常规CT策略(仅动态多期CT)与钆塞酸增强MRI策略(初始CT后追加钆塞酸增强MRI)两种初始检查策略。
- Markov队列模型模拟根治性或辅助治疗后患者,随访覆盖剩余预期寿命。
- 分析指标包括平均生命年增益、质量调整生命年、每人成本和增量成本效益比。
- 进行单因素、双因素和概率敏感性分析。
诊断标准与关键数值
- 常规CT策略生命 expectancy 7.22年、质量调整生命年5.08。
- 钆塞酸增强MRI策略生命 expectancy 7.79年、质量调整生命年5.52。
- 美国预期每人成本:常规CT策略99,770美元,钆塞酸增强MRI策略105,025美元。
- 钆塞酸增强MRI较常规CT的增量成本效益比为11,957美元,低于50,000美元/质量调整生命年的成本效益阈值。
- 单因素、双因素和概率敏感性分析在可接受范围内结果不变。
临床应用与阅片要点
- 作者认为,对可接受根治性治疗(肝移植除外)的早期肝细胞癌患者,CT后追加钆塞酸增强MRI用于分期管理具有成本效益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We determined the cost-effectiveness of two different diagnostic imaging strategies in guiding curative treatment of early-stage hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: We developed a decision analytic model using as its starting point a cohort of patients aged 55 years with early-stage HCC detected at dynamic multiphasic CT and with Child-Pugh class A cirrhosis. The model compared two strategies on the initial workup: conventional CT strategy using dynamic multiphasic CT only and gadoxetic acid-enhanced MRI strategy using additional gadoxetic acid-enhanced MRI after initial CT. A Markov cohort model simulated a cohort of patients after curative or adjuvant treatment, with follow-up over the remaining life expectancy. We analyzed mean life-years gain, quality-adjusted life-years (QALYs), costs per person, and incremental cost-effectiveness ratio (ICER). To evaluate results, we performed one-way, two-way, and probabilistic sensitivity analyses.
RESULTS: The life expectancies and QALY were 7.22 years and 5.08 for the conventional CT strategy and 7.79 years and 5.52 for the gadoxetic acid-enhanced MRI strategy, respectively. The expected costs were $99,770 for conventional CT and $105,025 for gadoxetic acid-enhanced MRI in the United States. The ICER with gadoxetic acid-enhanced MRI was $11,957, as opposed to that with conventional CT, which was lower than the cost-effectiveness threshold of $50,000/QALY. One-way, two-way, and probabilistic sensitivity analyses showed unchanged results over an acceptable range.
CONCLUSION: Gadoxetic acid-enhanced MRI after CT is cost-effective for detecting additional HCC in patients with early-stage HCC who can undergo curative treatment (besides liver transplantation). The cost-effectiveness of gadoxetic acid-enhanced MRI may be considered in the management of patients with early-stage HCC during staging.
引用
- Suh CH, Kim KW, Park SH, et al. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. AJR Am J Roentgenol. 2017. PMID: 29091004. doi:10.2214/AJR.17.18300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。